Navigating Glioblastoma Diagnosis and Care: Transformative Pathway of Artificial Intelligence in Integrative Oncology.

Glioblastoma multiforme (GBM), an aggressive brain tumor with high recurrence rates and limited survival, presents a pressing need for accurate and timely diagnosis. The interpretation of MRI can be complex and subjective. Artificial Intelligence (AI) has emerged as a promising solution, leveraging its potential to revolutionize diagnostic imaging. Radiomics treats images as numerical data and extracts intricate features from images, including subtle patterns that elude human observation. By integrating radiomics with genetics through radiogenomics, AI aids in tumor classification, identifying specific mutations and genetic traits. Furthermore, AI's impact extends to treatment planning. GBM's heterogeneity and infiltrative growth complicate delineation for treatment purposes. AI-driven segmentation techniques provide accurate 2D and 3D delineations, optimizing surgical and radiotherapeutic planning. Predictive features like angiogenesis and tumor volumes enable AI models to anticipate postop complications and survival rates. It can also aid in distinguishing posttreatment radiation effects from tumor recurrence. Despite these merits, concerns linger. The quality of medical data, transparency of AI techniques, and ethical considerations require thorough addressing. Collaborative efforts between neurosurgeons, data scientists, ethicists, and regulatory bodies are imperative for AI's ethical development and implementation. Transparent communication and patient consent are vital, fostering trust and understanding in AI-augmented medical care. In conclusion, AI holds immense promise in diagnosing and managing aggressive brain tumors like GBM. Its ability to analyze complex radiological data, integrate genetics, and aid in treatment planning underscores its potential to transform patient care. However, carefully considering ethical, technical, and regulatory aspects is crucial for realizing AI's full potential in oncology.